Takizawa Y, Inokuma S, Tanaka Y, Saito K, Atsumi T, Hirakata M, Kameda H, Hirohata S, Kondo H, Kumagai S, Tanaka Y
Department of Allergy and Immunological Diseases, Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, 3-18-22 Honkomagome, Tokyo 113-8677, Japan.
Rheumatology (Oxford). 2008 Sep;47(9):1373-8. doi: 10.1093/rheumatology/ken231. Epub 2008 Jun 24.
To survey and elucidate the clinical characteristics of CMV infection in rheumatic disease patients.
A detailed questionnaire survey on CMV infection was carried out against rheumatic disease patients hospitalized in member hospitals, and the obtained clinical and/or laboratory data were analysed.
Out of 7377 patients, 151 were diagnosed as having CMV infection. The underlying diseases ranged broadly, but SLE, microscopic polyangiitis, and dermatomyositis were the most common. Four were diagnosed histopathologically, and the others via positive CMV antigenaemia. In addition to oral corticosteroid for all but one patient, 81 were treated with pulsed methylprednisolone (MPSL), 64 with cyclophosphamide (CYC) and 36 with other immunosuppressants. Forty-four had a fatal outcome, for which presence of clinical symptoms, other infectious complications, lymphopenia, an older age (>59.3 yrs) and the use of pulsed MPSL were significant risk factors (P < 0.05) by univariate analysis. Multivariate analysis retained the first three (P < 0.05). The CMV antigenaemia count was significantly higher for the symptomatic than asymptomatic [10.1 (0.0-2998.0) vs 4.0 (1.3-1144.4)/10(5) PMNs, respectively, P < 0.05; threshold count: 5.6/10(5) PMNs]. No treatment benefit by anti-viral agent was observed as for survival.
CMV infection was mostly diagnosed by antigenaemia, and occurred among patients under strong immunosuppressive therapy using pulsed MPSL and/or immunosuppressants. Lymphopenia, presence of symptoms and other infections are significant risk factors for a poor outcome and pulsed MPSL and an older age may predict it. Patients were prone to be symptomatic with anti-genaemia count over 5.6/10(5) PMNs.
调查并阐明风湿性疾病患者巨细胞病毒(CMV)感染的临床特征。
对成员医院住院的风湿性疾病患者进行了关于CMV感染的详细问卷调查,并对获得的临床和/或实验室数据进行了分析。
在7377例患者中,151例被诊断为CMV感染。基础疾病范围广泛,但系统性红斑狼疮(SLE)、显微镜下多血管炎和皮肌炎最为常见。4例经组织病理学诊断,其余经CMV抗原血症阳性诊断。除1例患者外,所有患者均接受口服糖皮质激素治疗,81例接受脉冲式甲泼尼龙(MPSL)治疗,64例接受环磷酰胺(CYC)治疗,36例接受其他免疫抑制剂治疗。44例患者死亡,单因素分析显示,临床症状、其他感染并发症、淋巴细胞减少、年龄较大(>59.3岁)以及使用脉冲式MPSL是显著的危险因素(P<0.05)。多因素分析保留了前三项(P<0.05)。有症状患者的CMV抗原血症计数显著高于无症状患者[分别为10.1(0.0 - 2998.0)对4.0(1.3 - 1144.4)/10⁵中性多形核白细胞(PMN),P<0.05;阈值计数:5.6/10⁵PMN]。未观察到抗病毒药物对生存率有治疗益处。
CMV感染大多通过抗原血症诊断,发生在使用脉冲式MPSL和/或免疫抑制剂进行强免疫抑制治疗的患者中。淋巴细胞减少、症状的存在和其他感染是预后不良的显著危险因素,脉冲式MPSL和年龄较大可能可预测预后。当抗原血症计数超过5.6/10⁵PMN时患者容易出现症状。